Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;28(47):2300187.
doi: 10.2807/1560-7917.ES.2023.28.47.2300187.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Angela Mc Rose  1 , Nathalie Nicolay  2 , Virginia Sandonis Martín  3 , Clara Mazagatos  4   5 , Goranka Petrović  6 , Joaquin Baruch  7 , Sarah Denayer  8 , Lucie Seyler  9 , Lisa Domegan  10 , Odile Launay  11   12   13 , Ausenda Machado  14 , Cristina Burgui  15   5 , Roberta Vaikutyte  16 , F Annabel Niessen  17 , Isabela I Loghin  18   19 , Petr Husa  20   21 , Nassera Aouali  22 , George Panagiotakopoulos  23 , Kristin Tolksdorf  24 , Judit Krisztina Horváth  25 , Jennifer Howard  1 , Francisco Pozo  3 , Virtudes Gallardo  26 , Diana Nonković  27 , Aušra Džiugytė  7 , Nathalie Bossuyt  8 , Thomas Demuyser  9 , Róisín Duffy  10 , Liem Binh Luong Nguyen  12 , Irina Kislaya  14 , Iván Martínez-Baz  15   5 , Giedre Gefenaite  28   16 , Mirjam J Knol  17 , Corneliu Popescu  29   30 , Lenka Součková  21 , Marc Simon  31 , Stella Michelaki  23 , Janine Reiche  24 , Annamária Ferenczi  25 , Concepción Delgado-Sanz  4   5 , Zvjezdana Lovrić Makarić  6 , John Paul Cauchi  7 , Cyril Barbezange  8 , Els Van Nedervelde  9 , Joan O'Donnell  10 , Christine Durier  32 , Raquel Guiomar  14 , Jesús Castilla  15   5 , Indrė Jonikaite  16 , Patricia Cjl Bruijning-Verhagen  33   17 , Mihaela Lazar  34 , Regina Demlová  20 , Gil Wirtz  31 , Marina Amerali  23 , Ralf Dürrwald  24 , Mihály Pál Kunstár  25 , Esther Kissling  1 , Sabrina Bacci  2 , Marta Valenciano  1 ; I-MOVE-COVID-19 hospital study team  35 ; VEBIS hospital study team  35 ; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)
Collaborators, Affiliations

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Angela Mc Rose et al. Euro Surveill. 2023 Nov.

Abstract

IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.

Keywords: COVID-19; Europe; SARS-CoV-2; hospital; omicron; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Countries and study sites participating in I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, by provision of data for this analysis, Europe, 2021–2022
Figure 2
Figure 2
Exclusions, I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, Europe, 2021–2022 (n = 8,093)
Figure 3
Figure 3
Number of SARI patients by case status and week of COVID-19 vaccination or swab (complete primary series and booster doses), by vaccine product, I-MOVE-COVID-19 and VEBIS hospital vaccine effectiveness studies, Europe, 2021–2022 (n = 5,141)
See this image and copyright information in PMC

References

    1. European Medicines Agency (EMA). COVID-19 medicines. Amsterdam: EMA. [Accessed: 7 Mar 2023]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-thr...
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201. 10.1056/NEJMoa2101544 - DOI - PMC - PubMed
    1. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23. 10.1056/NEJMoa2101765 - DOI - PMC - PubMed